secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001104659-25-029687
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma reports FY2024 net loss of $166.5M; CEO Werner Cautreels retiring, Iain D. Dukes Interim CEO
--------------------------------------------------------------------------------

- Net loss of $166.5M ($35.21/share) for FY2024, driven by $117.5M acquired IPR&D and $24.4M warrant expense.
- Cash, cash equivalents and short-term investments $21.3M as of Dec 31, 2024; cash runway into Q1 2026.
- CEO Werner Cautreels retiring as of March 31, 2025; Interim CEO Iain D. Dukes appointed, continuing as Chairman.
- Lead candidate tivoxavir marboxil shows positive efficacy in three animal models for H5N1 bird flu; Phase 1 complete; FDA interaction sought under Animal Rule.
- R&D expense $12.8M (up $1.4M); G&A expense $12.3M (up $3.2M) for FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925029687/0001104659-25-029687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925029687/tm2510891d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer